Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.46 |
| ▸ | NT5E | P21589 | 11/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987313 | 0.94 | NT5E (0.44) | PDE2ANT5ECYP3A4CYP2C9 | |
| SCHEMBL19987157 | 0.94 | NT5E (0.44) | PDE2ANT5ECYP3A4CYP2C9 | |
| SCHEMBL19987209 | 0.93 | NT5E (0.45) | NT5ECYP3A4CYP2C9 | |
| SCHEMBL19987203 | 0.92 | NT5E (0.44) | PDE2ANT5ECYP3A4CYP2C9 | |
| SCHEMBL19987169 | 0.89 | NT5E (0.42) | NT5ECYP3A4CYP2C9 | |
| SCHEMBL19987346 | 0.89 | NT5E (0.40) | NT5ECYP3A4CYP2C9 | |
| SCHEMBL21511172 | 0.87 | NT5E (0.48) | NT5ECYP3A4CYP2C9 | |
| SCHEMBL19987158 | 0.87 | NT5E (0.53) | NT5E | |
| SCHEMBL19987172 | 0.86 | CYP3A4 (0.41) | NT5ECYP3A4CYP2C9 | |
| SCHEMBL19987159 | 0.86 | CYP3A4 (0.43) | NT5ECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | PNP, TYMP, MTAP | PDE2A 2895/4885NT5E 63/4885CYP3A4 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.